For GATA1, the median expression level for the pooled survival analysis could not be considered a significant marker for metastatic relapse-free survival with a total of 3875 breast cancer patients (HR = 1.07; 95% CI: 0.94–1.21, p-value = 0.2936, Fig. 4A). This evidence concerns the gene GATA1 and breast cancer.